Share

Innovent Biologics Inc (1801.HKEX) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+79.9%

1801.HKEX does not currently pay dividends

1. Investment Thesis — Base Case

The central tension is that Innovent earns its profits two ways and the market conflates them. Partnering upfronts from Takeda and Pfizer are lumpy, contracted and non-recurring by construction; product revenue compounding at 57% is the durable engine. Over five years the partnering cash funds global Phase 3 work while mazdutide and the newer launches grow into a paid-for cost base — offset by relentless NRDL and generic price deflation. The base case is respectable compounding at a multiple that slowly deflates as earnings catch up, not a re-rating melt-up.

H1 2026 product revenue of RMB 8.2bn annualises near RMB 17bn; the RMB 35-40bn 2030 target implies roughly 22-25% CAGR.
At 25-30x 2030 net income of roughly US$1.1-1.4bn, equity value reaches US$30-40bn against today's US$22.2bn.
Per share that is HK$165-175 by late 2031 after modest issuance — mid-teens annual compounding, not a doubling.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in HKD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (HKD)
Observed price	2021-09-17	66.5
Observed price	2021-10-07	76.2
Observed price	2021-10-19	78.0
Observed price	2021-10-31	69.2
Observed price	2021-11-04	67.4
Observed price	2021-11-16	79.0
Observed price	2021-11-28	72.0
Observed price	2021-12-18	53.0
Observed price	2021-12-22	50.3
Observed price	2022-01-07	40.2
Observed price	2022-01-15	43.4
Observed price	2022-02-04	31.3
Observed price	2022-02-12	30.6
Observed price	2022-02-28	35.0
Observed price	2022-03-04	32.0
Observed price	2022-03-16	25.4
Observed price	2022-04-05	29.3
Observed price	2022-04-13	26.6
Observed price	2022-04-21	25.5
Observed price	2022-05-07	19.59
Observed price	2022-05-15	19.28
Observed price	2022-06-04	25.2
Observed price	2022-06-16	25.6
Observed price	2022-06-28	37.0
Observed price	2022-07-14	38.5
Observed price	2022-07-22	34.9
Observed price	2022-08-03	31.9
Observed price	2022-08-11	36.8
Observed price	2022-08-27	34.2
Observed price	2022-09-08	27.1
Observed price	2022-09-12	28.7
Observed price	2022-09-24	24.0
Observed price	2022-10-10	22.9
Observed price	2022-10-26	29.6
Observed price	2022-10-30	27.6
Observed price	2022-11-15	34.9
Observed price	2022-12-05	27.8
Observed price	2022-12-13	32.4
Observed price	2022-12-21	30.9
Observed price	2023-01-02	34.6
Observed price	2023-01-10	37.6
Observed price	2023-01-26	46.2
Observed price	2023-02-03	45.6
Observed price	2023-02-23	39.4
Observed price	2023-02-27	37.6
Observed price	2023-03-15	42.7
Observed price	2023-03-31	35.1
Observed price	2023-04-12	40.5
Observed price	2023-04-16	41.5
Observed price	2023-05-02	36.4
Observed price	2023-05-14	39.9
Observed price	2023-05-30	36.6
Observed price	2023-06-07	37.1
Observed price	2023-06-23	30.4
Observed price	2023-07-01	29.7
Observed price	2023-07-13	32.7
Observed price	2023-07-29	35.9
Observed price	2023-08-06	30.3
Observed price	2023-08-22	30.9
Observed price	2023-08-30	36.0
Observed price	2023-09-07	35.4
Observed price	2023-09-27	40.9
Observed price	2023-10-01	38.0
Observed price	2023-10-13	44.5
Observed price	2023-11-06	48.4
Observed price	2023-11-14	44.5
Observed price	2023-11-30	45.8
Observed price	2023-12-08	39.8
Observed price	2023-12-24	39.2
Observed price	2024-01-01	42.6
Observed price	2024-01-13	40.1
Observed price	2024-01-21	34.9
Observed price	2024-02-02	31.9
Observed price	2024-02-18	39.2
Observed price	2024-03-05	39.1
Observed price	2024-03-13	43.9
Observed price	2024-03-17	42.4
Observed price	2024-04-06	36.0
Observed price	2024-04-18	33.7
Observed price	2024-04-26	39.1
Observed price	2024-05-04	40.8
Observed price	2024-05-24	35.9
Observed price	2024-06-01	34.9
Observed price	2024-06-17	38.0
Observed price	2024-06-21	36.8
Observed price	2024-07-07	38.4
Observed price	2024-07-23	40.9
Observed price	2024-07-27	38.4
Observed price	2024-08-16	40.9
Observed price	2024-08-28	44.1
Observed price	2024-09-09	41.8
Observed price	2024-09-13	44.0
Observed price	2024-09-25	42.4
Observed price	2024-10-07	49.8
Observed price	2024-10-19	46.1
Observed price	2024-10-31	33.8
Observed price	2024-11-16	36.8
Observed price	2024-11-28	39.1
Observed price	2024-12-10	38.1
Observed price	2024-12-22	35.1
Observed price	2024-12-30	36.1
Observed price	2025-01-19	31.2
Observed price	2025-01-23	31.6
Observed price	2025-02-08	36.3
Observed price	2025-02-16	38.2
Observed price	2025-02-28	40.5
Observed price	2025-03-12	38.9
Observed price	2025-04-01	48.9
Observed price	2025-04-09	42.2
Observed price	2025-04-25	54.4
Observed price	2025-05-03	54.8
Observed price	2025-05-15	50.0
Observed price	2025-05-23	58.6
Observed price	2025-06-12	80.8
Observed price	2025-06-28	77.7
Observed price	2025-07-06	83.8
Observed price	2025-07-10	80.3
Observed price	2025-07-30	98.5
Observed price	2025-08-11	90.0
Observed price	2025-08-23	99.6
Observed price	2025-08-27	91.0
Observed price	2025-08-31	103
Observed price	2025-09-20	92.9
Observed price	2025-10-02	101
Observed price	2025-10-30	80.7
Observed price	2025-11-03	90.2
Observed price	2025-11-07	85.2
Observed price	2025-11-27	96.2
Observed price	2025-12-01	94.8
Observed price	2025-12-17	80.8
Observed price	2026-01-02	78.8
Observed price	2026-01-14	89.5
Observed price	2026-01-18	86.7
Observed price	2026-02-03	78.8
Observed price	2026-02-23	92.0
Observed price	2026-03-03	80.0
Observed price	2026-03-23	77.5
Observed price	2026-03-27	85.5
Observed price	2026-03-31	84.9
Observed price	2026-04-16	92.4
Observed price	2026-04-28	82.6
Observed price	2026-05-02	91.2
Observed price	2026-05-30	82.5
Observed price	2026-06-07	74.4
Observed price	2026-06-11	73.0
Observed price	2026-07-01	82.5
Observed price	2026-07-09	86.3
Observed price	2026-07-21	92.2
Observed price	2026-08-02	86.2
Observed price	2026-08-10	97.3
Observed price	2026-08-26	110
Observed price	2026-09-11	93.5
Observed price	2026-09-15	95.0
Observed price	2026-09-23	103
Observed price	2026-09-25	99.7
Published advisor forecast	2026-09-18	96.6
Published advisor forecast	2026-12-18	102
Published advisor forecast	2027-03-18	98.3
Published advisor forecast	2027-06-18	106
Published advisor forecast	2027-09-18	111
Published advisor forecast	2027-12-18	115
Published advisor forecast	2028-03-18	122
Published advisor forecast	2028-06-18	116
Published advisor forecast	2028-09-18	124
Published advisor forecast	2028-12-18	129
Published advisor forecast	2029-03-18	133
Published advisor forecast	2029-06-18	139
Published advisor forecast	2029-09-18	134
Published advisor forecast	2029-12-18	142
Published advisor forecast	2030-03-18	147
Published advisor forecast	2030-06-18	152
Published advisor forecast	2030-09-18	159
Published advisor forecast	2030-12-18	154
Published advisor forecast	2031-03-18	162
Published advisor forecast	2031-06-18	169
Published advisor forecast	2031-09-18	174

2. Scenarios & Signals

Bull case

The bull case activates when a global Phase 3 readout replaces biobucks with booked milestones. A positive IBI363 lung-cancer result around 2029 triggers large Takeda payments, validates the 40% US profit share, and forces the market to value Innovent as a global oncology principal rather than a China licensor. Simultaneously the oral GLP-1 assets attract a Western obesity partner, decoupling the metabolic franchise from domestic price deflation. Earnings and multiple expand together, delivering returns well beyond mid-teens compounding.

Bear case

The bear case activates when generic semaglutide turns China obesity into a commodity market before scales. Eleven-plus entrants crush realised price, the NRDL declines full obesity reimbursement, and product revenue stalls near RMB 20bn while R&D at a fifth of sales keeps consuming margin. Milestone income then looks like what it is — episodic and contingent — and a 66x trailing multiple compresses toward a China-domestic pharma rating. Add US licensing restrictions and the globalisation premium disappears entirely.

Current crowd narrative

The consensus treats Innovent as China's validated out-licensing champion: RMB 13.0bn FY2025 revenue, first full-year profit, US$34bn of headline partnered deal value, Hang Seng Index membership. Sell-side extrapolates 57% H1 product growth toward the RMB 35-40bn 2030 target and prices 66x trailing earnings as reasonable. The anchoring bias is treating biobucks as revenue and treating 's price as durable.

Alpha-gap assessment

The crowd modestly underestimates this equity, though not for the reason it thinks. It over-credits the US$34bn of contingent milestones while under-crediting the mundane fact that capex fell to 5.24% of revenue and gross margin held at 76.7% — the infrastructure is paid for, so incremental product sales now convert to profit at rates the 6.2% FY2025 net margin badly conceals. Meanwhile the shares trade 14% below the HK$112.56 a fully-diligenced Takeda paid in December 2025 [6]. Modest underpricing, not a deep discount.

Convergence catalyst

The FY2026 results in March 2027 are the trigger: a full year of product revenue near RMB 17-18bn with net margin stepping into double digits would prove the operating leverage rather than the milestone story. First sign of repricing is the shares reclaiming the HK$112.56 Takeda strike.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: 0.2
Expected volatility regime: high_erratic
Convergence-cycle position: momentum

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Mazdutide's DUAL Agonist HEAD Start	Mazdutide is the world's only approved GCG/GLP-1 dual agonist for obesity and type 2 diabetes, approved in China June 2025 [13][14]. Phase 3 data at 9mg indicate weight loss ahead of semaglutide [15][18], which supports premium positioning even as generics flood the category. This underwrites the 57% H1 2026 product-revenue growth [2] and converts, at a 77% gross margin, into the operating leverage that turns revenue into earnings through 2030.	Not available	+30.0%
BIG Pharma PAYS THE R&d BILL	Takeda paid US$1.2bn upfront including equity issued at HK$112.56, with up to US$10.2bn in milestones and a 60/40 global cost split on IBI363 [6][7]; Pfizer added US$650m upfront plus US$9.85bn contingent across twelve programmes, closed July 2026 [8][9][11]. Innovent externalises late-stage development cost while retaining US profit participation. That structure converts a cash-hungry pipeline into funded optionality and lifts the multiple investors will pay for pipeline duration.	Not available	+25.0%
Operating Leverage ON A 77% Gross Margin	The fixed-cost base is now built: capex fell to 5.24% of FY2025 revenue from 43.3% in 2021, while gross margin held at 76.7%. Operating margin swung from -68.5% (FY2022) to +5.63% (FY2025), and H1 2026 IFRS net profit rose 50% to RMB 1.3bn on 45% revenue growth [2]. Each incremental RMB of product sales now drops far more to the bottom line; this is the dominant earnings mechanism through 2030.	Not available	+22.0%
A RMB 30bn WAR Chest IN A 4% World	Cash reserves of RMB 30.2bn (~US$4.5bn) at 31 July 2026 equal roughly a fifth of market capitalisation [2], with debt-to-equity of just 0.15 in FY2025. With the Fed at 3.75%-4.00% and US 10Y near 5%, peers dependent on equity issuance face punitive financing; Innovent does not. That balance sheet funds MRCT Phase 3 programmes without dilutive emergency raises and earns meaningful interest income, insulating reported earnings during the transition.	Not available	+12.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Semaglutide's Cliff CUTS BOTH WAYS	Semaglutide lost China patent protection on 20 March 2026, with at least eleven generics in late-stage trials expected to launch at a fraction of branded cost [15][16][17]. The consensus frames this as market expansion; the arithmetic is price deflation across the entire China GLP-1 category, including mazdutide's realised price per patient. Volume growth will partly be paid for with price, compressing the revenue-per-script assumption embedded in a 66x trailing multiple.	Not available	-20.0%
THE NRDL Price Ratchet	China's reimbursement negotiation and volume-based procurement systematically extract price for access, and obesity indications have historically struggled for coverage. With Jan-August fixed investment down 7.2% and nominal retail sales up only 0.4% YoY, fiscal pressure on provincial health budgets intensifies the annual haircut. Each renewal cycle resets mazdutide, tafolecimab and picankibart pricing downward, meaning reported revenue growth persistently understates the underlying unit growth Innovent must deliver.	Not available	-15.0%
Duration Compression AT A 5% Tenor	The US 10-year closed near 4.998% after the unanimous 16 September Fed hike to 3.75%-4.00%, and the HKD peg imports that discount rate directly into Hong Kong equity valuation. Innovent's value sits disproportionately in 2029-2033 cash flows from IBI363 and the next-generation obesity pipeline. A higher risk-free rate mechanically shrinks their present value; at 66x trailing earnings the multiple, not the business, carries the rate sensitivity.	Not available	-14.0%
Sintilimab's SLOW Bleed	TYVYT, the legacy revenue anchor, sits in China's most price-competitive class: domestic PD-1 pricing has collapsed under repeated NRDL rounds and multi-entrant competition. Gross margin already slipped from 86.6% in FY2021 to 76.7% in FY2025, consistent with mix shifting toward lower-priced and biosimilar-adjacent products. This erosion runs beneath headline growth, forcing newer launches to replace declining base revenue before they add to it.	Not available	-10.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Ibi363 Clears A Global Phase 3	IBI363, the PD-1/IL-2 bispecific behind the Takeda deal, began global Phase 3 work in non-small-cell lung cancer from late 2025 [19]. A positive pivotal readout plausibly lands in 2029-2030, triggering large development milestones within the US$10.2bn contingent package and validating a 40% US profit share on a potential multi-billion-dollar asset [6][7]. That would reframe Innovent from a China-domestic earner to a global oncology principal. It stays below 50% because oncology bispecific Phase 3 attrition remains high and timelines slip routinely.	30.0%	+60.0%
Obesity Franchise GOES EX China	A Western partner licensing mazdutide or the next-generation oral GLP-1 assets (IBI3032, IBI3042) or amylin candidate IBI3040 for global rights [5] would deliver a headline upfront comparable to the Takeda and Pfizer transactions and, crucially, decouple the obesity thesis from China price deflation. Most plausibly negotiated in 2027-2029 as oral GLP-1 Phase 2 data mature. Probability stays under 50% because global obesity partners already hold internal oral programmes, limiting the buyer set and the price they will pay.	25.0%	+40.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Washington Closes THE Licensing DOOR	BIOSECURE-style legislation, outbound investment rules or CFIUS-adjacent restrictions on China-origin clinical assets would impair the very mechanism that funds Innovent's globalisation: upfronts and milestones from Takeda and Pfizer [6][8]. A statutory restriction enacted in 2027-2029 would strand contingent milestones, remove the US profit-share optionality and force a re-rating toward a China-only pharmaceutical multiple. Probability is below 50% because existing deals are contracted and large US pharma lobbies hard against disrupting its own pipeline sourcing.	20.0%	-35.0%
GLP 1 Price WAR Meets NRDL Refusal	If eleven-plus semaglutide generics trigger an outright price war while the NRDL declines or deeply discounts mazdutide's obesity indication, the franchise becomes a volume business at commodity economics [15][16]. Realised price per patient could fall faster than scripts grow, stalling product revenue near RMB 20bn and rendering the RMB 35-40bn 2030 target unreachable [5]. Most likely visible in the 2027 and 2028 reimbursement rounds. It remains below 50% because dual-agonist differentiation and hospital formulary inertia provide partial insulation.	35.0%	-30.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_578437c4-bc83-586d-9e9b-ed742a49375c__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (HKD)	Scenario rationale
1	December 18, 2026	+6.0%	102.40	Q4 delivers the 2026 NRDL outcome and continued mazdutide script growth. Hang Seng passive flows and the visible gap to Takeda's HK$112.56 entry price support a modest recovery into year-end.
2	March 18, 2027	-4.0%	98.30	A further Fed hike toward the 4.1% median and a US 10Y holding near 5% compress long-duration biotech multiples. China biotech de-rates broadly despite Innovent's intact operating momentum.
3	June 18, 2027	+8.0%	106.16	FY2026 results confirm product revenue near RMB 17bn with net margin stepping into double digits. Proof of operating leverage, rather than milestone lumpiness, drives the first genuine re-rating leg.
4	September 18, 2027	+5.0%	111.47	H1 2027 interim results track toward the RMB 20bn full-year target. Next-generation oral GLP-1 Phase 2 progress adds pipeline credibility while energy-driven inflation keeps global risk appetite contained.
5	December 18, 2027	+3.0%	114.82	The 2027 NRDL round delivers a price haircut on mazdutide's obesity indication, trimming enthusiasm. Volume growth still offsets, leaving a muted but positive quarter on unchanged full-year guidance.
6	March 18, 2028	+6.0%	121.71	FY2027 results meet the RMB 20bn revenue target. Confirmation of the first published milestone, combined with an easing rate environment as US inflation normalises, supports multiple stabilisation.
7	June 18, 2028	-5.0%	115.62	Generic semaglutide penetration and Hengrui's ribupatide bite into realised GLP-1 pricing. The market recalibrates revenue-per-patient assumptions, compressing the metabolic franchise's implied contribution.
8	September 18, 2028	+7.0%	123.71	Interim IBI363 global Phase 3 progress and additional MRCT programme starts refocus attention on the oncology optionality that Takeda and Pfizer capital underwrites. Sentiment rotates back toward pipeline value.
9	December 18, 2028	+4.0%	128.66	R&D intensity moderates as a share of revenue while the approved portfolio broadens. Incremental margin expansion becomes visible in guidance, supporting steady appreciation into the year-end close.
10	March 18, 2029	+3.0%	132.52	FY2028 results show mid-twenties revenue growth with net margin in the low teens. Solid but unspectacular; the market awaits pivotal oncology data before paying a higher multiple.
11	June 18, 2029	+5.0%	139.15	Progress toward the five-MRCT-Phase-3 commitment and early US regulatory interactions build anticipation. Global rate normalisation lifts the present value of Innovent's back-loaded cash-flow profile.
12	September 18, 2029	-4.0%	133.58	Geopolitical noise around China-origin asset licensing resurfaces, plus a soft interim on legacy PD-1 revenue. Investors discount the globalisation premium temporarily, pressuring the multiple.
13	December 18, 2029	+6.0%	141.60	Pivotal IBI363 data begin to emerge. Partial validation triggers development milestone recognition under the Takeda agreement, converting contingent biobucks into reported cash for the first time at scale.
14	March 18, 2030	+4.0%	147.26	FY2029 results position revenue on track toward the RMB 35-40bn 2030 goal. Margin benchmarking against top-tier peers becomes credible, supporting earnings-driven rather than narrative-driven appreciation.
15	June 18, 2030	+3.0%	151.68	First US or European launch preparation absorbs commercial spend, capping near-term margin. Growth remains intact but investors discount the cost of building an ex-China commercial organisation.
16	September 18, 2030	+5.0%	159.26	The 2030 revenue target comes into range and the profit-share economics on co-developed US assets begin contributing. Earnings quality improves as product revenue dominates the milestone contribution.
17	December 18, 2030	-3.0%	154.48	A crowded next-generation obesity market — orals and amylins from multiple global entrants — prompts a reassessment of Innovent's metabolic terminal value. Modest consolidation after a strong run.
18	March 18, 2031	+5.0%	162.21	FY2030 results confirm delivery near the RMB 35-40bn target with margins benchmarked to top-tier biopharma. The multiple compresses but earnings growth more than compensates.
19	June 18, 2031	+4.0%	168.70	Global commercial operations contribute measurable revenue, diversifying away from NRDL price risk. Investors begin valuing Innovent on blended developed-market comparables rather than China-domestic multiples.
20	September 18, 2031	+3.0%	173.76	Maturing growth profile settles into high-teens revenue expansion with sustained double-digit net margin. The stock compounds with earnings rather than re-rating, closing the horizon near HK$174.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Innovent Announces 2025 Annual Results and Business Updatesprnewswire.com
[2]Innovent Announces 2026 Interim Results And Strategic Vision Toward 2030rttnews.com
[3]Innovent Biologics, Inc. — Corporate Intelligence & Market Pulse | BriefGlancebriefglance.com
[4]Innovent Announces 2025 Annual Results and Business Updates | Nasdaqnasdaq.com
[5]Innovent Announces 2026 Interim Results and Business Updates - BioSpacebiospace.com
[6]Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapiesfinance.yahoo.com
[7]TAKEDA PHARMACEUTICAL CO LTD - Form 20-F - FY2026sec.gov
[8]Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines | Pfizerpfizer.com
[9]Pfizer and Innovent Biologics Enter $10.5 Billion Oncology Drug Development Partnership for 12 Cancer Programsbio-itworld.com
[10]Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billioncnbc.com
[11]PFIZER INC - Form 10-Q - FY2026sec.gov
[12]Innovent Announces 2026 Interim Results and Business Updates | The Manila Timesmanilatimes.net
[13]Innovent Biologicsen.wikipedia.org
[14]Innovent Announces 2026 Interim Results and Business Updatesfinance.yahoo.com
[15]China’s obesity drug makers take on global giants as Novo Nordisk patent expiresscmp.com
[16]China’s GLP-1 Patent Cliff: What 2026 Means for the Global Weight Loss Market - Lengealengealaw.com
[17]Chinese drugmakers prep for looming semaglutide generics horizonfinance.yahoo.com
[18]China’s weight-loss drug makers take on global giants as Novo Nordisk patent expires – Chin@Strategychinastrategy.org
[19]Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assetsfiercebiotech.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Sherlock Holmes — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.